Press Release

IntrinsiQ Summit: Top Oncology Market Experts Examine Clinical and Economic Bellwethers

Emergence of Oral Chemotherapy a Central Theme at 5th Annual Pharmaceutical Client Meeting

WALTHAM, Mass. (Sep 14, 2010) IntrinsiQ, the company improving the quality and understanding of cancer care, today brings oncology experts and practitioners together to discuss the sweeping trends and forces that will impact every stakeholder in the extended continuum of care: pharmaceutical researchers, physicians and nurses, pharmacy groups and payors.  

At IntrinsiQ’s fifth annual pharmaceutical client meeting, held today in Bridgewater, New Jersey, attendees will gain a deep understanding of the clinical and economic pressures that physician practices face, emerging reimbursement models and – most importantly – how the growing options for oral chemotherapy delivery will reshape the future of oncology care.

Sessions will inform both the design and interpretation of market research. Speakers and topics include:

•    Mary Kruczynski, Community Oncology Alliance (COA), Director Policy Analysis will share the findings of recent research on oral oncolytics, conducted in conjunction with Avalere Health. Drawing on her experience working with COA members and all levels of government – including Congress and CMS – to develop oncology care policies, she will detail the barriers to access and use, the inconsistency of payer approaches, and opportunities to engage stakeholders when oral oncolytics are involved.  

•     Michael (Mick) Koerner, R. Ph., Director of Pharmacy Services, ION (International Oncology Network)will review a GPO/distributor approach to oral oncology medications and highlight solutions to overcome the barriers for using oral oncology medications, including in-office dispensing.

•    Dawn Holcombe, MBA, FACMPE, ACHE, President, DGH Consulting will share her bird’s-eye view of the oncology management market, with the confluence of three trends:

  • third-party organizations aggressively courting payors with promises to control costs of oncology care and drugs by a variety of means
  • physicians and cancer centers reacting with proposals and initiatives in the face of increasing payor policies and choices for care management
  • stakeholders questioning the role of physicians in medical decision-making and where oncology treatments should be delivered

•    Courtney Koster, R.N., IntelliDose Product Manager will discuss the first integrated e-prescribing tool for oncologists and detail the clinical prescribing workflows in practices.

The top pharmaceutical and biotechnology oncology companies rely on IntrinsiQ’s gold-standard data every month, collected through IntelliDose®, IntrinsiQ’s chemotherapy management solution, to understand how physicians truly practice and how therapies are being used.

 

About IntrinsiQ

IntrinsiQ, LLC is the leading provider of medical oncology clinical information systems and the premier source of US oncology data and analysis.  Each month, IntrinsiQ’s clinical software application, IntelliDose®, captures the treatment decisions and details from more than 750 oncologists, for nearly 20,000 patients, creating a database unrivaled in accuracy, detail and timeliness of information about the medical oncology care process.  IntelliDose ensures patient safety though automation and standards designed to meet the needs of a specific practice, saving staff time, maximizing reimbursement and reducing operating costs.  IntelliDose interfaces with leading EMR and hospital information systems, extending existing or planned technology investments to include cancer patient management. For more information, visit www.intrinsiq.com.

IntrinsiQ Company Contact:
781-647-1144
info@intrinsiq.com

IntrinsiQ Media Contact:
George Robertson
(617) 969-9192
grobertson@corporateink.com